PCL
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
PCL makes diagnostic test kits and instruments that detect infectious diseases, cancers, and other conditions from a blood sample, without surgery or a laboratory send-out.
Its products are used to screen blood supplies for high-risk viruses and to run point-of-care tests (rapid bedside or clinic tests) for conditions ranging from influenza to several cancer types, and it also supplies diagnostic kits for companion animals. Listed on KOSDAQ, Korea's tech and small-cap board, the company has expanded beyond diagnostics into supplying medicines for chronic diseases and into antimicrobial film materials and cosmetics derived from its core materials technology.
Summary is AI-generated and may contain errors · figures from DART filings
PCL in five facts
What does PCL do?
PCL makes diagnostic test kits and instruments that detect infectious diseases, cancers, and other conditions from a blood sample, without surgery or a laboratory send-out.
Where is PCL listed and in which sector?
PCL (Korean name: 피씨엘) trades under KRX code 241820 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is PCL?
Its market capitalisation was US$12.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were PCL's latest annual revenue and operating profit?
For fiscal year 2024, PCL reported revenue of US$940.6K, an operating loss of US$20.5M and a net loss of US$39.9M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 85.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2024, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.